Citadel Advisors
TXG icon

Citadel Advisors’s 10x Genomics TXG Stock Holding History

Citadel Advisors’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$107M Buy
2,779,213
+2,035,479
+274% +$53.3M 0.01% 928
2026
Q1 		$15.8M Buy
743,734
+612,914
+469% +$12.3M ﹤0.01% 2622
2025
Q4 		$2.13M Buy
+130,820
New +$1.98M ﹤0.01% 5787
2025
Q3 		– Sell
-195,944
Closed -$2.55M – 14155
2025
Q2 		$2.27M Sell
195,944
-868,322
-82% -$7.92M ﹤0.01% 5467
2025
Q1 		$9.29M Sell
1,064,266
-942,092
-47% -$11.9M ﹤0.01% 2958
2024
Q4 		$28.8M Sell
2,006,358
-773,612
-28% -$12.2M 0.01% 1788
2024
Q3 		$62.8M Buy
2,779,970
+2,445,577
+731% +$50.6M 0.01% 1023
2024
Q2 		$6.5M Buy
334,393
+247,234
+284% +$6.47M ﹤0.01% 3363
2024
Q1 		$3.27M Sell
87,159
-27,066
-24% -$1.19M ﹤0.01% 4633
2023
Q4 		$6.39M Buy
114,225
+98,920
+646% +$4.3M ﹤0.01% 3461
2023
Q3 		$631K Sell
15,305
-706,265
-98% -$36.7M ﹤0.01% 7561
2023
Q2 		$40.3M Sell
721,570
-508,557
-41% -$27.5M 0.01% 1222
2023
Q1 		$68.6M Sell
1,230,127
-233,774
-16% -$10.9M 0.02% 849
2022
Q4 		$53.3M Buy
1,463,901
+1,108,820
+312% +$36.3M 0.01% 1076
2022
Q3 		$10.1M Buy
355,081
+222,348
+168% +$8.47M ﹤0.01% 2741
2022
Q2 		$6.01M Buy
+132,733
New +$6.89M ﹤0.01% 3473
2022
Q1 		– Sell
-5,616
Closed -$491K – 14602
2021
Q4 		$837K Sell
5,616
-59,506
-91% -$9.11M ﹤0.01% 8380
2021
Q3 		$9.48M Sell
65,122
-10,108
-13% -$1.74M ﹤0.01% 3176
2021
Q2 		$14.7M Buy
75,230
+72,604
+2,765% +$13.1M ﹤0.01% 2502
2021
Q1 		$475K Sell
2,626
-203,255
-99% -$35.1M ﹤0.01% 9783
2020
Q4 		$29.2M Buy
205,881
+89,316
+77% +$13M 0.01% 1420
2020
Q3 		$14.5M Buy
116,565
+114,008
+4,459% +$12M ﹤0.01% 1870
2020
Q2 		$228K Sell
2,557
-25,504
-91% -$1.99M ﹤0.01% 8342
2020
Q1 		$1.75M Buy
28,061
+4,443
+19% +$347K ﹤0.01% 4363
2019
Q4 		$1.8M Sell
23,618
-81,852
-78% -$4.92M ﹤0.01% 4582
2019
Q3 		$5.32M Buy
+105,470
New +$5.84M ﹤0.01% 3023

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Citadel Advisors's TXG Position: Q2 2026 in Review

Citadel Advisors increased its 10x Genomics (TXG) stake by 274% in Q2 2026, buying an estimated $53.3M and bringing the position to 2,779,213 shares worth $107M. The position accounts for 0.01% of the portfolio, ranked #928.

Citadel Advisors first reported a position in TXG in Q3 2019 and has held it in 26 quarters since. 391 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • Citadel Advisors held 2,779,213 shares of 10x Genomics worth $107M as of Q2 2026.
  • Citadel Advisors bought 2,035,479 10x Genomics shares in Q2 2026, an estimated $53.3M.
  • 10x Genomics made up 0.01% of Citadel Advisors's portfolio in Q2 2026, its #928 holding.
  • Citadel Advisors first reported a position in 10x Genomics in Q3 2019 and has held it in 26 quarters since.
  • 391 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.